NetworkNewsBreaks – Oncotelic Therapeutics, Inc.
Post# of 76
(Total Views: 52)
Posted On: 11/21/2025 4:22:48 PM
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Biotech Valuation Trends
Oncotelic Therapeutics (OTCQB: OTLC) was highlighted in a BioMedWire editorial examining how fair-value remeasurements under GAAP are becoming key indicators of real scientific and commercial progress in late-stage biotech pipelines. The piece notes that Oncotelic is preparing for a significant fair-value remeasurement of its 45% stake in JV entity GMP Bio following a new independent valuation suggesting a potential step-up in asset value, reinforcing the company’s position as it advances its oncology efforts.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Oncotelic Therapeutics (OTCQB: OTLC) was highlighted in a BioMedWire editorial examining how fair-value remeasurements under GAAP are becoming key indicators of real scientific and commercial progress in late-stage biotech pipelines. The piece notes that Oncotelic is preparing for a significant fair-value remeasurement of its 45% stake in JV entity GMP Bio following a new independent valuation suggesting a potential step-up in asset value, reinforcing the company’s position as it advances its oncology efforts.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)